Diltiazem in atrial fibrillation: effectiveness, safety, drug-sparing properties

Cover Page

Cite item

Full Text

Abstract

The article discusses current algorithm for choice of drugs for rate control in atrial fibrillation. It is shown that algorithm use in clinical practice may lead to excessive prescribing of digoxin and b-blockers compared to non-dihydropyridine calcium antagonists. A modified algorithm is proposed to extend indications for use of diltiazem. A rationale is provided for diltiazem-apixaban combination to reduce the cost of anticoagulation therapy.

About the authors

S. N Beldiev

Tver State Medical University of the Ministry of Health of the Russian Federation

Email: sbeldiev@yandex.ru
канд. мед. наук, доц. каф. внутренних болезней ФДПО ГБОУ ВПО Тверской ГМУ 170100, Russian Federation, Tver, ul. Sovetskaja, d. 4

References

  1. Национальные рекомендации по диагностике и лечению фибрилляции предсердий. 2012. http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf
  2. Vaughan-Sarrazin M.S, Mazur A, Chrischilles E, Cram P. Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. Am Heart J 2014; 168 (1): 53-9.e1.
  3. Lip G.Y, Laroche C, Dan G.A et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-19.
  4. Kotecha D, Holmes J, Krum H et al. on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Efficacy of b blockers in patients with heart failure plus atrial fibrillation: an individual - patient data meta - analysis. Lancet 2014; 384: 2235-43.
  5. Farshi R, Kistner D, Sarma J.S et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open - label study of five drug regimens. J Am Coll Cardiol 1999; 33: 304-10.
  6. Rathore S.S, Curtis J.P, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-8.
  7. Khan S.S, Gheorghiade M. Digoxin use in atrial fibrillation: a critical reappraisal. Lancet 2015; 385: 2330-2.
  8. Bauman J.L, Di Domenico R.J, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006; 166: 2539-45.
  9. Bangalore S, Makani H, Radford M et al. Clinical outcomes with b - blockers for myocardial infarction: a meta - analysis of randomized trials. Am J Med 2014; 127: 939-53.
  10. Messerli F.H, Hansen J.F, Gibson R.S et al. Heart rate - lowering calcium antagonists in hypertensive post - myocardial infarction patients. J Hypertens 2001; 19: 977-82.
  11. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta - blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
  12. Skanes A.C, Healey J.S, Cairns J.A et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-36.
  13. Ulimoen S.R, Enger S, Carlson J et al. Comparison of four single - drug regimens on ventricular rate and arrhythmia - related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013; 111: 225-30.
  14. Ulimoen S.R, Enger S, Pripp A.H et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta - blockers in patients with permanent atrial fibrillation. Eur Heart J 2014; 35: 517-24.
  15. National Clinical Guideline Centre (UK). Atrial fibrillation: The management of atrial fibrillation. London: National Institute for Health and Care Excellence (UK), 2014. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068959/pdf/TOC.pdf
  16. Frost C.E, Byon W, Song Y et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015; 79: 838-46.
  17. Food and Drug Administration. ELIQUIS (apixaban) tablets for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s006lbl.pdf
  18. Food and Drug Administration: Center for drug evaluation and research. Apixaban (Eliquis): clinical pharmacology and biopharmaceutical review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf
  19. ФАРМ-индекс - российский фармпортал, цены в аптеках, наличие лекарств на рынке. http://www.pharmindex.ru
  20. Martin J.E, Daoud A.J, Schroeder T.J, First M.R. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317-37.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies